Table 3.
Outcomes associated with the 4 induction agents
| Basiliximab (n = 3,049) | Daclizumab (n = 1,501) | Thymoglobulin (n = 4,466) | Alemtuzumab (n = 999) | P | |
|---|---|---|---|---|---|
| Rejection within 12 months1 | 168 (6.8) | 62 (5.1) | 170 (5.0) | 50 (6.8) | 0.013 |
| Died | 634 | 324 | 679 | 152 | |
| Cause of death missing (27.2% overall) | 252 (28.4) | 98 (23.2) | 271 (28.5) | 46 (23.2) | 0.090 |
| Cardiac death | 215 (33.9) | 100 (30.9) | 199 (29.3) | 55 (36.2) | 0.193 |
| Infectious death | 119 (18.8) | 58 (17.9) | 150 (22.1) | 32 (21.1) | 0.329 |
| Malignancy death | 70 (11.0) | 43 (13.3) | 93 (13.7) | 16 (10.5) | 0.416 |
Data presented as n (%) for categorical variables.
1
Includes any use of medications to treat rejection within the first year after transplant in those patients whose allograft survived at least 12 months.